Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation

Wang, Li and Fritschel, Elyse and Baser, Onur (2013): Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation. Published in: Journal of Health Economics and Outcomes Research (JHEOR) , Vol. 1, No. 1 (2013): pp. 42-53.

Abstract

Background: Atrial fibrillation (AF) is a common clinical problem and potent risk factor for stroke. However, real-world effectiveness and outcomes for AF patients are not well described. Objective: To compare the economic and clinical impact of stroke and warfarin use on patients with nonvalvular atrial fibrillation (NVAF). Methods: This was a retrospective analysis of medical and pharmacy claims of NVAF patients from a large commercial health insurance database (01/01/2005-12/31/2007). Patients were grouped according to stroke or warfarin prescription status. For all groups, demographic, clinical, and pharmaceutical characteristics were analyzed descriptively. Risk-adjusted overall and cardiovascular-related hospital readmission rates in 30 days, length of stay (LOS), clinical outcomes, and health care costs were assessed using propensity score matching. Costs were adjusted to 2007 U.S. dollars using the medical component of the U.S. Consumer Price Index.

• Item Type: MPRA Paper
• Language: English
• Keywords: retrospective, NVAF, stroke, cardiovascular, propensity score matching, economic, clinical
• Subjects: C - Mathematical and Quantitative Methods > C0 - General; I - Health, Education, and Welfare > I0 - General

References

1.Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-73.

2.Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001;37(2):371-8.

3.Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors In Atria Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5.

4.Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147(9):1561-4.

5.Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(1 suppl):194S-206S.

6.Fuster V, Ryden LE, Asinger RW, et al. American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38(4):1231-66.

7.Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154(13):1449- 57.

8.Helgason CM, Wolf PA: American Heart Association Prevention Conference IV: prevention and rehabilitation of stroke—executive summary. Circulation 1997;96(2):701-7.

9.Jørgensen HS, Nakayama H, Reith J, et al. Stroke recurrence: predictors, severity, and prognosis—The Copenhagen Stroke Study. Neurology 1997;48(4):891-5.

10.Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158(3):229-34.

11.Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994;47(11):1245-51.

12.de Groot V, Beckerman H, Lankhorst GJ, Bouter LM: How to measure comorbidity a critical review of available methods. J Clin Epidemiol 2003;56(3):221-9.

13.Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613-9.

14.Horton JD, Bushwick BM: Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician 1999;59(3):635-46.

15.Delaney JA, Opatrny L, Prophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007;177(4):347-51.

16.Yamaguchi T: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial filbrillation. Stroke 2000;31:817-21.

17.EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.